Sio Capital Management LLC Grows Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Sio Capital Management LLC lifted its position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 18.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,214,239 shares of the company’s stock after acquiring an additional 505,831 shares during the quarter. PMV Pharmaceuticals comprises about 1.9% of Sio Capital Management LLC’s portfolio, making the stock its 17th biggest holding. Sio Capital Management LLC owned about 0.06% of PMV Pharmaceuticals worth $4,789,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Public Employees Retirement System of Ohio grew its holdings in shares of PMV Pharmaceuticals by 174.2% during the first quarter. Public Employees Retirement System of Ohio now owns 22,757 shares of the company’s stock worth $39,000 after buying an additional 14,457 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in PMV Pharmaceuticals by 71.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 42,802 shares of the company’s stock worth $73,000 after buying an additional 17,858 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of PMV Pharmaceuticals in the 2nd quarter worth $101,000. Evoke Wealth LLC acquired a new position in shares of PMV Pharmaceuticals during the 2nd quarter valued at about $102,000. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of PMV Pharmaceuticals by 570.8% in the second quarter. Cubist Systematic Strategies LLC now owns 69,867 shares of the company’s stock valued at $113,000 after purchasing an additional 59,452 shares during the period. Hedge funds and other institutional investors own 90.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Oppenheimer upgraded shares of PMV Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Friday, November 8th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of PMV Pharmaceuticals in a research note on Tuesday, August 20th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $5.80.

PMV Pharmaceuticals Stock Up 0.6 %

NASDAQ:PMVP opened at $1.60 on Friday. PMV Pharmaceuticals, Inc. has a fifty-two week low of $1.40 and a fifty-two week high of $3.47. The company has a 50 day moving average price of $1.58 and a 200 day moving average price of $1.63.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). On average, sell-side analysts anticipate that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current year.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.